44 results about "Papillary thyroid cancer" patented technology

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.

The objective of the present invention is to provide a pharmaceutical composition and a therapeutic method that are specifically effective against at least one disease selected from multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract.4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and analogs thereof are specifically effective against at least one disease selected from multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

The invention discloses a papillary thyroid cancer pathological image classification method based on deep learning, and mainly solves the problem of poor classification effect on papillary thyroid cancer pathological images in the prior art. According to the scheme, the method comprises the following steps: 1) reading a papillary thyroid cancer pathological section image with an amplification factor of 20, and inputting the papillary thyroid cancer pathological section image into an improved VGG-f convolutional neural network to obtain an attention heat map; 2) normalizing the attention diagram to obtain a discrimination force region position; reading a 40-time amplified thyroid cancer pathological image and obtaining an image block according to the position of the discrimination area; 3)inputting the image blocks into an original VGG-f network, constructing a loss function, and performing supervised training on the network; 4) extracting trained VGG-f network convolution features andperforming classification processing to obtain categories of the image blocks, and 5) judging the categories of the thyroid cancer pathological images according to the categories of the image blocks.The classification accuracy is high, and the method can be used for classifying the thyroid cancer papillary cancer pathological images by a computer.

The present invention features compositions and methods for characterizing thyroid lesions (e.g., benign follicular adenomas (FAs), papillary thyroid carcinomas (PTC) and follicular variant papillary thyroid carcinomas (FVPTCs)).

It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6 / STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

The invention discloses an ultrasonic image identification method and an ultrasonic image identification device for papillary thyroid carcinoma. The ultrasonic image identification method comprises the step of identifying features of a papillary thyroid carcinoma ultrasonic image to be identified by adopting a pre-established papillary thyroid carcinoma ultrasonic image identification model. The establishment process of the papillary thyroid carcinoma ultrasonic image identification model comprises the steps of: preprocessing papillary thyroid carcinoma ultrasonic images used for deep learning; normalizing the pre-processed papillary thyroid carcinoma ultrasonic images used for deep learning; establishing a convolutional neural network; and training the papillary thyroid carcinoma ultrasonic images used for deep learning after normalization by utilizing the convolutional neural network, so as to obtain the papillary thyroid carcinoma ultrasonic image identification model. The ultrasonic image identification method and the ultrasonic image identification device can perform accurate identification on the features of the papillary thyroid carcinoma ultrasonic image to be identified in the using process, so as to assist the diagnosis of a doctor, reduce the uncertainty of diagnosis and improve the accuracy of the diagnosis.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

The invention relates to a gene relevant to papillary thyroid tumors and an application thereof. According to the base sequence of the gene, real-time and quantitative PCR (Polymerase Chain Reaction) primers are designed and synthesized; the expression level of long-chain non-coding RNA (Ribonucleic Acid) transcribed by the gene is detected in a papillary thyroid carcinoma clinical case specimen; the result shows remarkable reducing of the expression level of the long-chain non-coding RNA in papillary thyroid tumor tissues and the long-chain non-coding RNA of the gene silencing can remarkably promote the growth of thyroid cancer cells. The gene relevant to the papillary thyroid tumors is expected to prepare preparations used in papillary thyroid carcinoma auxiliary diagnosis, gene therapy, curative effect prediction or prognosis.

The invention provides methods and kits for diagnosing a growth in a subject by providing a sample of a growth taken from a subject, determining the level of midkine or pleiotrophin in the sample by an immunoassay, and comparing the level of midkine or pleiotrophin determined from the sample with a control. An increased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a malignant growth, whereas an equivalent or decreased level of midkine or pleiotrophin in the sample as compared to the control is diagnostic of a benign growth. Growth refers to, for example, papillary thyroid cancer (PTC).

Provided herein are methods for identifying a subject with an increased likelihood of developing or having metastatic papillary thyroid cancer (PTC), or a subject with an increased likelihood of developing or having recurrent PTC, and the treatment of such a subject.

The invention discloses a kit for early diagnosis of papillary thyroid carcinoma. A primer sequence is as follows: TP53INP1 Sense:5'-CTTAACAATGTTCCAGAGGCTGAAT-3'Antisense:5'-AGGGTGCTCAGT AGGTGACTCTT-3'; TP53INP2Sense:5'-:5'-GGTCCGTGTTGCACCTAA-3'; Antisense:5'-TTGGATCCCACCATGGAGGGCGC-3'AXIN2Sense:5'-5'-CACGGAAACTGTTGACAGTGGATAC-3'; Antisense:5'-GGTGGCTGGTGC AAAGACATAG-3'' GAPDH Sense:5'-GCACCGTC AAGGCTGAGAAC-3'; and Antisense:5'-TGGTGAAGACGCCCAGTGGA-3'. The kit disclosed by the invention has high sensitivity and high specificity, and can be used for a screening and early diagnosis technology of the papillary thyroid carcinoma.

The invention relates to the technical field of medical diagnostics. Thyroid tumors can be divided into two types including benign tumors and cancers. The property of a thyroid nodule is difficult to determine clinically; and even if biopsy is carried out, the benign tumors and the cancers are not easy to clearly identify due to thyroid adenomas and focal nodular hyperplasia. The invention provides a blood micro-molecular metabolin specific chromatogram which is used for identifying papillary thyroid carcinomas, benign thyroid tumors and blood of normal people, and a manufacturing method of the blood micro-molecular metabolin specific chromatogram. A micro-molecular metabolin comprises two blood metabolin marks, namely palmityl carnitine and carnitine; the molecular weights of the palmityl carnitine and the carnitine are 400.2634 and 161.20; and corresponding ions detected on a mass spectrum are 404.5532 and 160.7866. A clinical experiment shows that the accuracy of applying a chromatogram formed by a specific value of the two metabolism micro-molecules to judge the thyroid cancer is 74% and the accuracy of judging non-cancer (the benign thyroid tumor and the normal people) is 72.3%. The blood micro-molecular metabolin specific chromatogram disclosed by the invention has the advantage of high sensitivity and can be prepared into a diagnosis kit for screening and auxiliary diagnosis of the thyroid cancer.

This invention relates, e.g., to a method for detecting the presence of lymph node metastases in a subject having papillary thyroid carcinoma (PTC), comprising measuring in a sample from the subject the amount of expression (e.g., the amount of protein, or the amount of mRNA encoding the protein) of one or more of the following proteins: (a) LIMD2, and / or (b) PTPRC, and / or (c) LTB, and / or (d) CD48, and / or (e) ABCC3, wherein a significant amount of over-expression of one or more of protein(s) (a)-(e), compared to the baseline value, indicates that lymph node metastases are likely to be present in the subject.

The invention relates to new application of a KCNK2 gene, in particular to application of the KCNK2 gene and an expression product thereof to treatment of papillary thyroid carcinoma as tumor markers .In order to diagnose thyroid carcinoma more accurately and avoid missed diagnosis and misdiagnosis, tumor molecular markers are screened based on sequencing and data analysis, the result shows that the KCNK2 gene can be used for preparing a papillary thyroid carcinoma auxiliary diagnosis and treatment preparation, and quite good clinical application value is achieved.

The invention discloses a 22-abeo-stigmasterol benzimidazole compound as well as a preparation method and application thereof. The structural formula of the 22-abeo-stigmasterol benzimidazole compound is shown in the specification; experiments for in-vitro inhibition of growth and proliferation activities of cancer cells show that the 22-abeo-stigmasterol benzimidazole compound prepared by the preparation method has remarkable inhibition effect to multiple tumor cell strains such as human papillary thyroid cancer cells, human oral epidermoid carcinoma cells, cancer cell strains of cervical cancer and the like. Meanwhile, the 22-abeo-stigmasterol benzimidazole compound has no cytotoxicity to human kidney epithelial cells (HEK293T) and can be applied to the preparation of drugs for treating cancers.

Methods of treating a disease or disorder characterized by cells with increased or aberrant expression of cytokeratin-8 (CK8) are disclosed. The methods typically include administering to a subject in need thereof a pharmaceutical composition including an effective amount of a CK8 inhibitor. Exemplary diseases include thyroid cancers, particularly thyroid cancers characterized by poorly differentiated or undifferentiated cells. In the most preferred embodiments the cancer is an anaplastic thyroid cancer or a poorly differentiated papillary thyroid cancer. Disclosed inhibitors include, functional nucleic acids, inhibitory anti-CK8 antibodies, inhibitory peptides, and small molecules.

SNX5 is detected in a sample collected from a subject. SNX5 can be used as a tumor marker specific to papillary thyroid carcinoma, whereby the diagnosis of papillary thyroid carcinoma can be achieved readily. A technique for detecting papillary thyroid carcinoma using the tumor marker is also provided.

The invention relates to a novel use of sanguinarine chloride and especially relates to a use of sanguinarine chloride in preparation of a drug for treating a thyroid cancer. In-vivo and in-vitro thyroid cancer experiments prove that sanguinarine chloride has effects of inhibiting or killing thyroid cancer cells, has human papilloma thyroid cancer cells IHH-4 and human anaplastic thyroid cancer cells ASH-3 growth IC50 values of 1.44 micromoles per liter and 2.62 micromoles per liter, and reduces a survival rate of thyroid cancer cells to less than 10%. A nude-mice in-vivo anti-cancer experiment proves that sanguinarine chloride has a transplantation tumor inhibition ratio of 80.81%.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

The invention provides an miRNA detection kit based on a sulfo-modified loop-mediated isothermal amplification method. The miRNA detection kit consists of a loop-mediated amplification reaction solution, an enzyme, a primer and probe mixed solution and a standard substance. Dumbbell-shaped DNA formed by connecting a base sulfo-modified linker probe Linker A / B in the presence of target miRNA is used as an amplicon and is combined with the same part of base sulfo-modified FIP / BIP primers to initiate LAMP exponential amplification; a sulfo-modified DNA structure can further enhance the amplification efficiency, the formed amplification product opens a signal probe-molecular beacon to generate a fluorescence signal, and the fluorescence signal of the target product is monitored by a real-timefluorescence quantitative PCR instrument, so that the target miRNA is detected, and the miRNA detection kit has the characteristics of strong stability, good specificity and high sensitivity. The miRNA detection kit can be used for detecting various miRNAs in serum of a papillary thyroid cancer patient, and can be used as a tumor marker for auxiliary diagnosis of papillary thyroid cancer.

The invention relates to the technical field of medical diagnostics, in particular to a blood micromolecular metabolite atlas for identifying papillary thyroid cancer, benign goiter or normal person, and a producing method thereof. The micromolecular metabolite comprises two blood metabolism markers, namely sphinganine 1-phosphate and hydroxybutyric acid which respectively have molecular weight of 453.2855 and 569.3481 as well as corresponding ions detected by mass spectroscopy of 454.2928 and 570.3547. Clinical experiment proves that the atlas has thyroid cancer judgment accuracy rate of 82% and non-cancer (benign goiter and normal person) judgment accuracy rate of 75.3%. The method provided by the invention has the advantages of high sensitivity and high flux, overcomes the defect that a non-invasive diagnosis method for diagnosing benign and malignant thyroid tubercle is lacking clinically at present, and is suitable for screening and assistant diagnosis of thyroid cancer.

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma, non small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocyctosis, mast cell leukemia, a disease caused by c-Abl kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof, or a disease caused by c-Kit kinase, oncogenic forms thereof, aberrant fusion proteins thereof and polymorphs thereof.